Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000358
Collaborator
University of Pennsylvania (Other)
0
1
Study Details
Study Description
Brief Summary
The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
21 Years
to 59 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 6178 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- University of Pennsylvania
Investigators
- Principal Investigator: Charles O'Brien, M.D., Ph.D., PDVAMC Treatment Research Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000358
Other Study ID Numbers:
- NIDA-3-0012-7
- Y01-3-0012-7
First Posted:
Sep 21, 1999
Last Update Posted:
Jan 12, 2017
Last Verified:
Dec 1, 2002
Additional relevant MeSH terms: